Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | December 10, 2020 | December 10, 2020 |
| NovoCure LtdNVCR · Entity 4494 | Director | May 21, 2019 | May 22, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date December 10, 2020 · Filed December 10, 2020
This filing explicitly reported no securities owned.
NovoCure Ltd
Report date May 21, 2019 · Filed May 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 6,145 |
Reported balance
After 2019-05-21 transaction · row 1
1 source rowRow 1 · 2019-05-21 · Exercise / conversion · Acquired 6,145 · Balance 6,145 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-21 · Exercise / conversion · Disposed 6,145 · Balance 0 F1: Fully vested as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2019 Filed May 22, 2019 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 6,145 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032062 · doc4.xml · derivative · entry 2 Burkoth William T. · CIK 0001654261 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,145 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 21, 2019 Filed May 22, 2019 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 6,145 | $48.87 | $300,306.15 |
DisclosureSEC source: 0001209191-19-032062 · doc4.xml · nonDerivative · entry 1 Burkoth William T. · CIK 0001654261 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 6,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035383 · doc4.xml · derivative · entry 2 Burkoth William T. · CIK 0001654261 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,145 Underlying: Ordinary Shares · 6,145 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders. F3 · derivative.expiration_date: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 12,345 | $0.00 Strike: $31.45 | $0.00 |
DisclosureSEC source: 0001209191-18-035383 · doc4.xml · derivative · entry 1 Burkoth William T. · CIK 0001654261 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,345 Underlying: Ordinary Shares · 12,345 shares Expires 2028-05-31 F1 · derivative.exercise_date: Options to buy 12,345 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders. Read SEC document |
| May 10, 2017 Filed May 12, 2017 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 23,600 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001209191-17-031877 · doc4.xml · derivative · entry 1 Burkoth William T. · CIK 0001654261 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,600 Underlying: Ordinary Shares · 23,600 shares Expires 2027-05-10 F1 · derivative.exercise_date: Options to buy 23,600 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the date of the Company's 2018 annual general meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.